We have an active clinical trials program that provides patients with cutting-edge treatment for cancer to help advance the field of oncology.
We offer a wide range of clinical trials from supportive care to treatment trials, including Phase 1 clinical trials. Through collaboration with MSU College of Nursing, we’re able to offer alternative therapy and supportive care advances through clinical trials.
Our participation in national cooperative groups trials, supported by the National Cancer Institute at the National Institutes of Health (NIH). We are a lead member site for NRG Oncology and have participated in federally funded trials for several years.
MSU Breslin Cancer Center is a founding member of the Big Ten Cancer Research Consortium. The Big Ten cancer centers have teamed up with a united mission to transform the conduct of cancer research through collaboration. This creates a network of academic institutions working together and conducting innovative clinical trials using expertise of Big Ten universities.
We have advocated patient access to cancer trials for more than 45 years and are dedicated to research-driven activities that lead to a better quality of life for individuals and communities.
View our active clinical trials below or call our office at 517-975-9547.
Donate now. Support the Department of Medicine Oncology/Hematology Research Fund.
The U.S. National Institues of Health provides a good primer for patient and families about clinical trials. Access the information at ClinicalTrials.gov.
ALEXION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (pnh) REGISTRY: A multi-center, multi-national, observational registry with enrollment of patients who are diagnosed with PNH and also PNH patients not receiving Soliris therapy. NCT#01374360 | Anas Al-Janadi, MD
BIG TEN BTCRC-BRE15-016: A single arm Phase II study of palbociclib in combination with tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer. NCT#02668666 | Deimante Tamkus, MD
NOVARTIS CBYL719C2301: A Phase II randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and post menopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment. NCT#02437318 | Deimante Tamkus, MD
NRG B-55: A randomised, double-blind, parallel group, placebo-controlled multi-center Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment AND neoadjuvant OR adjuvant chemotherapy. NCT#02032823 | Deimante Tamkus, MD
Medivation MDV-3100-20: A Phase 3, randomized, international study comparing the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy versus placebo with paclitaxel in patients with advanced, diagnostic-positive, triple-negative breast cancer.
SWOG S1207: Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor-positive and HER2/neu negative breast cancer. NCT#01674140 | Deimante Tamkus, MD
VERTEX VX12-970-001: An open-label, first-in-human study of the safety, tolerability, and pharmacokinetics of VX-970 in combination with cytotoxic chemotherapy in subjects with advanced solid tumors. NCT#01674140 | Deimante Tamkus, MD
NSABP MPR-1: A Study to collect and analyze tissue specimens from metastatic colorectal cancer (MCRC) patients for the development of molecularly profiled tissue repository for the primary purpose of maintaining a patient registry for future clinical trials based on the molecular profile of the tumors. NCT#01793805 | Deimante Tamkus, MD
NSABP C-13: Phase III randomized placebo-controlled study evaluating regorafenib following completion of standard chemotherapy for patients with Stage III colon cancer. NCT#02664077 | Borys Hrinczenko, MD
EMD SERONA EMR200647-001: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. For Second-Line or Sorafenib intolerant patients. Must be unresectable or advanced disease; Eligible if progression following 1 line of prior sorafenib therapy. NCT#02517398 | Borys Hrinczenko, MD
Incyte INCB-MA-MF-401: Prospective, longitudinal, non-interventional study of disease burden and treatment of patients with low-risk myelofibrosis OR high-risk essential thrombocytemia (ET) OR ET patients receiving ET-directed therapy (MOST Trial).
EMD SERONA EMR200647-001: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. NCT#01772004 | Borys Hrinczenko, MD
Merrimack MM-121-01-02-09: A Phase 2 study of MM-121 in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positivie, locally advanced or metastatic non-small cell lung cancer (SHERLOC Trial). NCT02387216 | Borys Hrinczenko, MD
VERTEX VX12-970-001: An open-label, first-in-human study of the safety, tolerability, and pharmacokinetics of VX-970 in combination with cytotoxic chemotherapy in subbjects with advanced solid tumors. NCT#02157792 | Deimante Tamkus, MD
Incyte INCB39110-206: An open-label phase ½ study of INCB039110 (Itacitinib) in combination with ibrutinib in subjects with relapsed or refractory diffuse large B-cell lymphoma. NCT#02760485 | Anas Al-Janadi, MD
CELGENE CONNECT MDS/AML REGISTRY: An observational study of patients with newly diagnosed (within 2 months) MDS or AML. Patients are excluded it they have received treatment with active agents for MDS or AML prior to ICF date. Supportive care treatments are allowed. NCT#01688011 | Anas Al-Janadi, MD
Incyte INCB-MA-MF-401: Prospective, longitudinal, non-interventional study of disease burden and treatment of patients with low-risk myelofibrosis OR high-risk essential thrombocytemia (ET) OR ET patients receiving ET-directed therapy (MOST Trial) NCT#02953704 | Anas Al-Janadi, MD
WYATT SMART TRIAL: Symptom Management (Strategies) Among Cancer patients with possible Reflexology, or Meditative Practices (gentle yoga, meditation and breathing exercises) NCT#02759146 | Deimante Tamkus, MD